BioLife Solutions/$BLFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioLife Solutions
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Ticker
$BLFS
Sector
Primary listing
Employees
159
Headquarters
Website
BLFS Metrics
BasicAdvanced
$1.3B
-
-$0.12
1.76
-
Price and volume
Market cap
$1.3B
Beta
1.76
52-week high
$29.55
52-week low
$19.10
Average daily volume
522K
Financial strength
Current ratio
4.43
Quick ratio
3.243
Long term debt to equity
3.341
Total debt to equity
3.391
Interest coverage (TTM)
-19.16%
Profitability
EBITDA (TTM)
0.506
Gross margin (TTM)
64.67%
Net profit margin (TTM)
-5.92%
Operating margin (TTM)
-5.21%
Effective tax rate (TTM)
-0.45%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-0.80%
Return on equity (TTM)
-5.66%
Valuation
Price to revenue (TTM)
13.289
Price to book
3.65
Price to tangible book (TTM)
9.99
Price to free cash flow (TTM)
117.6
Free cash flow yield (TTM)
0.85%
Free cash flow per share (TTM)
0.225
Growth
Revenue change (TTM)
68.16%
Earnings per share change (TTM)
-92.78%
3-year revenue growth (CAGR)
-14.18%
10-year revenue growth (CAGR)
31.79%
3-year earnings per share growth (CAGR)
-62.53%
10-year earnings per share growth (CAGR)
-9.13%
What the Analysts think about BLFS
Analyst ratings (Buy, Hold, Sell) for BioLife Solutions stock.
Bulls say / Bears say
Total revenue rose 29% year-over-year to $25.4 million in Q2 2025, driven by a 28% increase in cell processing platform revenue to $23.0 million (Nasdaq)
Full-year 2025 revenue guidance was upgraded to $100.0 million–$103.0 million, implying 22%–25% growth over 2024 and signaling strong visibility for the rest of the year (Nasdaq)
The acquisition of the remaining 90% of PanTHERA CryoSolutions in April 2025 reinforces BioLife’s biopreservation leadership by bringing in proprietary Ice Recrystallization Inhibitor technology and scientific expertise (SEC)
GAAP net loss increased to $15.8 million in Q2 2025 from $5.6 million in Q2 2024, highlighting ongoing unprofitability on a GAAP basis (SEC)
GAAP gross margin decreased to 62% in Q2 2025 from 64% a year earlier, and non-GAAP adjusted gross margin declined to 65% from 67%, signaling growing cost pressures and margin compression (SEC)
Significant revenue concentration risk persists, with cell processing representing about 91% of Q2 2025 revenue, leaving BioLife vulnerable to fluctuations in a single product line (SEC)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BLFS Financial Performance
Revenues and expenses
BLFS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioLife Solutions stock?
BioLife Solutions (BLFS) has a market cap of $1.3B as of September 08, 2025.
What is the P/E ratio for BioLife Solutions stock?
The price to earnings (P/E) ratio for BioLife Solutions (BLFS) stock is 0 as of September 08, 2025.
Does BioLife Solutions stock pay dividends?
No, BioLife Solutions (BLFS) stock does not pay dividends to its shareholders as of September 08, 2025.
When is the next BioLife Solutions dividend payment date?
BioLife Solutions (BLFS) stock does not pay dividends to its shareholders.
What is the beta indicator for BioLife Solutions?
BioLife Solutions (BLFS) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.